Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VIVO Cannabis Inc. VVCIF

Healthcare Drug Manufacturers - Specialty & Generic
VIVO Cannabis Inc is a Canada-based company. It is involved in the production and sale of medical and recreational cannabis and the provision of cannabis-related medical information and services in Canada. The company's operating segment includes Cannabis, Patient Clinics, and Corporate. It generates maximum revenue from the Cannabis segment. The company has a presence across three geographical locations - Canada, Germany, and Australia.


OTCQB:VVCIF - Post by User

VIVO Cannabis Inc. > Q3 and Q4 of 2019 to see uptick in Revenue and Growth. FWIW
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(177)
•••
Comment by srtman03on Sep 27, 2019 9:19am
144 Views
Post# 30170046

RE:Q3 and Q4 of 2019 to see uptick in Revenue and Growth. FWIW

RE:Q3 and Q4 of 2019 to see uptick in Revenue and Growth. FWIW
1hot-techwoman wrote: "We remain focused on increasing long-term shareholder value by continuing to establish ourselves as a premium provider of cannabis products and services. Our positive momentum is expected to lead to increased revenue generation and product breadth in the second half of the year." VIVO's net revenue increased slightly to $5.3 million during the second quarter of 2019 compared to the first quarter of 2019 as product supply remained essentially flat. The harvesting and packaging of the Company's increase licensed capacity is expected to result in growth in net revenue in the second half of 2019.


Only going to start to ramp up from here going forward $$$$$ Did you get your 100,000 filled at $0.33?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities